[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2010117233A3 - 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법 - Google Patents

플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법 Download PDF

Info

Publication number
WO2010117233A3
WO2010117233A3 PCT/KR2010/002193 KR2010002193W WO2010117233A3 WO 2010117233 A3 WO2010117233 A3 WO 2010117233A3 KR 2010002193 W KR2010002193 W KR 2010002193W WO 2010117233 A3 WO2010117233 A3 WO 2010117233A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
manufacturing
same
fluvastatin
composition containing
Prior art date
Application number
PCT/KR2010/002193
Other languages
English (en)
French (fr)
Other versions
WO2010117233A2 (ko
Inventor
김성욱
전성수
구자성
이준영
Original Assignee
한올바이오파마주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올바이오파마주식회사 filed Critical 한올바이오파마주식회사
Publication of WO2010117233A2 publication Critical patent/WO2010117233A2/ko
Publication of WO2010117233A3 publication Critical patent/WO2010117233A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 안정성을 증가시킨 플루바스타틴의 약제학적 조성물에 관한 것이다. 바람직하게는, 장기간 보관시 안정성이 향상된 플루바스타틴, 그의 약제학적으로 허용가능한 염 또는 그들의 이성질체를 포함하는, 고지혈증 또는 C형 간염의 예방 및 치료를 위한 플루바스타틴의 약제학적 조성물 및 그의 제조 방법에 관한 것이다.
PCT/KR2010/002193 2009-04-09 2010-04-09 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법 WO2010117233A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0030730 2009-04-09
KR1020090030730A KR101072600B1 (ko) 2009-04-09 2009-04-09 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법

Publications (2)

Publication Number Publication Date
WO2010117233A2 WO2010117233A2 (ko) 2010-10-14
WO2010117233A3 true WO2010117233A3 (ko) 2011-03-03

Family

ID=42936739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/002193 WO2010117233A2 (ko) 2009-04-09 2010-04-09 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법

Country Status (2)

Country Link
KR (1) KR101072600B1 (ko)
WO (1) WO2010117233A2 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050007A1 (en) * 1999-02-26 2000-08-31 Lipocine, Inc. Compositions and methods for improved delivery of hydrophobic therapeutic agents
US20040009961A1 (en) * 2000-04-19 2004-01-15 Borody Thomas Julius Composition and therapies for hyperlipidaemia-associated disorders
KR20080107129A (ko) * 2007-06-05 2008-12-10 충남대학교산학협력단 고콜레스테롤 치료용 복합제제 및 이의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050007A1 (en) * 1999-02-26 2000-08-31 Lipocine, Inc. Compositions and methods for improved delivery of hydrophobic therapeutic agents
US20020012680A1 (en) * 1999-02-26 2002-01-31 Patel Mahesh V. Compositions and methods for improved delivery of lipid regulating agents
US20040009961A1 (en) * 2000-04-19 2004-01-15 Borody Thomas Julius Composition and therapies for hyperlipidaemia-associated disorders
KR20080107129A (ko) * 2007-06-05 2008-12-10 충남대학교산학협력단 고콜레스테롤 치료용 복합제제 및 이의 제조방법

Also Published As

Publication number Publication date
WO2010117233A2 (ko) 2010-10-14
KR101072600B1 (ko) 2011-10-11
KR20100112292A (ko) 2010-10-19

Similar Documents

Publication Publication Date Title
NO2019042I1 (no) Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt
WO2010030359A3 (en) Macrocyclic hepatitis c serine protease inhibitors
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
MY173823A (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
EP2219616A4 (en) TAXAN DERIVATIVES LYOPHILIZED PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY AND MANUFACTURING METHOD THEREFOR
EP2100607A4 (en) PHARMACEUTICAL COMPOSITION HAVING ENHANCED STORAGE STABILITY
DK2282994T3 (da) 3-aminocarbazolforbindelse, farmaceutisk sammensætning indeholdende forbindelsen samt fremstillingsmetode derfor
WO2008130678A3 (en) Rosuvastatin intermediates and process for the preparation of rosuvastatin
WO2009147075A3 (en) Pharmaceutical compositions containing a crystalline form of posaconazole
HK1212157A1 (en) Low dose lipoic acid pharmaceutical compositions and methods
MY153608A (en) Use of dronedarone for the preparation of medicament for use in the prevention of cardiovascular hospitalization or of mortality
IL231170A (en) Nitrate mustard derivative compound, pharmaceutical preparation, use of drug preparation and compound for use as a drug
EP2220086A4 (en) DIPEPTIDYLPEPTIDASE IV-INHIBITABLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFOR AS ACTIVE AGENT
WO2011155793A3 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
EP2588106A4 (en) DELAYED RELEASED PHARMACEUTICAL COMPOSITION WITH PRAMIPEXOL OR A PHARMACEUTICALLY ALLOWED SALT AND INCREASED STABILITY
WO2010044585A3 (en) Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2010049449A3 (en) Novel salts of sunitinib
WO2012029074A3 (en) Pharmaceutical compositions of linezolid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761894

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10761894

Country of ref document: EP

Kind code of ref document: A2